Venrock Healthcare Capital Partners Discloses 7.1% Stake in Biocryst Pharmaceuticals Inc (BCRX)

Anders Hove and Bong Koh‘s VHCP Management owns a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as a new filing with the US Securities and Exchange Commision showed. The 13G filing revealed that VHCP Management holds 5.24 million shares of BioCryst, which represent 7.1% of the company’s outstanding stock. The fund did not report holding shares in its last 13F filing. BioCryst Pharmaceuticals’ stock has lost more than 70% since the beginning of the year.

Overall, during the fourth quarter, the number of funds bullish on BioCryst among those we track inched up by one to 15. Among them, the largest stake was held by Julian and Felix Baker‘s Baker Bros. Advisors, followed by Peter Kolchinsky’s RA Capital Management, which reported stakes worth $146.7 million and $31.9 million, respectively, in their last 13F filings. Other peers with similar optimism consist of D. E. Shaw’s D E Shaw, Daniel Gold’s QVT Financial and Bihua Chen’s Cormorant Asset Management.

Moreover, it’s important to mention that several funds initiated stakes in BioCryst Pharmaceuticals in the last three months of 2015. Among them, Jim Simons’ Renaissance Technologies reported the largest new position, worth $1.5 million. Other funds with new holdings include Michael S. Weiss and Lindsay A. Rosenwald’s Opus Point Partners Management, David Costen Haley’s HBK Investments and Joel Greenblatt’s Gotham Asset Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Page 1 of 19 – SEC Filing